StockData
ProKidney Corp. logo

ProKidney Corp. (PROK) stock

PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.10+0.06 (+5.77%)

Close on Nov 17, 2026Market cap $332.56MP/E –Yield –

ProKidney revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

ProKidney's revenue for the twelve months ending Jun 30, 2026 was $818.00K, up 55.2% year over year. For fiscal 2025 it was $893.00K, up 1075.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$893.00K+1075.0%
FY2024Dec 31, 2024$76.00K–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$150.00K-32.1%
Q1 FY2026Mar 31, 2026$226.00K-1.7%
Q4 FY2025Dec 31, 2025$225.00K+196.1%
Q3 FY2025Sep 30, 2025$217.00K–
Q2 FY2025Jun 30, 2025$221.00K–
Q1 FY2025Mar 31, 2025$230.00K–
Q4 FY2024Dec 31, 2024$76.00K–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$0–

More ProKidney figures

See a number that looks wrong?